ST
Sikerui (Taizhou) Biotechnology
China · Biotech
Sikerui (Taizhou) Biotechnology develops tumour-infiltrating lymphocyte cell therapies through research operations in Shanghai and Taizhou.
Product
Sikerui (Taizhou) Biotechnology is developing a third-generation tumour-infiltrating lymphocyte, or TIL, therapy programme. Led by founder Zhu Wenjun, the company combines research activity in Shanghai with laboratory development in Taizhou.
Its work involves growing cells and validating the therapy approach. Local support has helped the team obtain laboratory materials and establish operations as it moves its TIL programme through development.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Grant-to-equity project support — historical disclosure | Undisclosed | Participants not disclosed |